Breast Cancer Clinical Trial

A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors

Summary

This is a Phase 1b/Phase 2a, open-label, multicenter study to determine the safety, tolerability, recommended Phase 2 dose (RP2D), efficacy, pharmacokinetics (PK) and pharmacodynamic (PD) properties of idronoxil when rectally administered as a suppository (NOX66) to patients with any solid tumor (Part 1) and patients with metastatic castration-resistant prostate cancer (mCRPC), breast cancer (BC) and non-small-cell lung cancer (NSCLC) (Part 2) who are eligible for low-dose external beam radiotherapy (EBRT) for at least one symptomatic or minimally symptomatic lesion (for the prevention of symptoms).

View Full Description

Full Description

The study is divided into 2 parts: Part 1 (dose escalation) and Part 2 (dose expansion). The study design allows an exploration of different doses of NOX66 (800 mg, 1200 mg, 1600 mg and 2400 mg) with safety monitoring to ensure the safety of the patients. In Cycle 1, NOX66 will be administered for 14 days followed by a 7-day rest period on a 21-day cycle. From Cycle 2 onwards, NOX66 will be administered for 7 days followed by a 7-day rest period on a 14-day cycle. Patients will continue to receive NOX66 on a cyclical basis until disease progression, unacceptable toxicity, withdrawal of consent, start of a new anticancer therapy, withdrawal of the patient by the Investigator or termination of the study by the Sponsor.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patient has a minimum life expectancy of 6 months
Histological or cytological confirmation of prostate cancer, BC, NSCLC and any other solid tumors
Confirmed metastatic disease by imaging
Documented disease progression following first or later lines of anticancer systemic treatment
Patient is eligible for low-dose EBRT for at least one lesion
Patients with prior RT are eligible, only if there is no potential for field overlap between the prior RT and the planned RT
For patients with BC or NSCLC: Patient must have at least one measurable lesion as per RECIST v1.1 (in Part 2 only)
Patient has ECOG performance status of 0 to 2
Adequate bone marrow, renal, and liver function
Metastatic Castration-resistant Prostate Cancer: Baseline testosterone levels ≤ 14.4 ng/dL and ongoing medical castration must be maintained throughout the duration of the study; patient has evidence of symptomatic and/or progressive disease
Breast Cancer Patients: Known hormone receptor status (estrogen receptors/progesterone receptors or estrogen receptors alone). Breast cancer patients are allowed to be on background hormonal treatment.

Exclusion Criteria:

Patient has tumor involvement of the central nervous system
Impaired cardiac functioning or clinically significant cardiac disease
Uncontrolled hypertension despite two concomitant antihypertensive therapies
Patients who have had a colectomy (total or left hemicolectomy) with re-anastomosis
Patients for whom administration of the suppositories are likely to cause pain or difficulties in absorption
Patients with fecal impaction or uncontrolled irritable bowel disease
Patients with inflammatory bowel disease
Any other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding that, in the Investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent
Patients with oligometastatic disease (fewer than 5 metastatic lesions) amenable to standard therapy will be excluded
Patients who have had RT to the region of the rectum or will require RT to the region of the rectum during the trial
Uncontrolled active infection requiring intravenous antibiotic, antiviral or anti-fungal medications within 14 days before the first dose administration
Receiving or having received anticancer treatment
Patient has received corticosteroids at a dose of > 10 mg prednisone/day or equivalent for any reason within 4 weeks prior to receiving the first dose administration
Patient is not willing to use suppositories
Patient has a positive reverse transcription polymerase chain reaction (RT-PCR) test for severe acute respiratory coronavirus 2 (SARS-CoV-2) prior to Screening or enrollment, or has clinical signs and symptoms consistent with SARS-CoV-2 infection; e.g., fever, dry cough, dyspnea, sore throat, fatigue or positive SARS-CoV-2 test result within 2 weeks prior to Screening.

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

100

Study ID:

NCT04957290

Recruitment Status:

Recruiting

Sponsor:

Noxopharm Limited

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Beverly Hills Cancer Center
Beverly Hills California, 90211, United States More Info
Gabayan Afshin
Contact
The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center
Houston Texas, 77030, United States More Info
Dr. Chad Tang
Contact

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 1

Estimated Enrollment:

100

Study ID:

NCT04957290

Recruitment Status:

Recruiting

Sponsor:


Noxopharm Limited

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.